Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
JOURNAL OF CLINICAL ONCOLOGY. Bd. 40. H. 16. 2022
Erscheinungsjahr: 2022
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Lueftner, Diana (Autor)
Brucker, Cosima (Autor)
Decker, Thomas (Autor)
Fasching, Peter A. (Autor)
Goehler, Thomas (Autor)
Jackisch, Christian (Autor)
Janssen, Jan (Autor)
Koehler, Andreas (Autor)
Luedtke-Heckenkamp, Kerstin (Autor)
Van Mackelenbergh, Marion (Autor)
Marme, Frederik (Autor)
Nusch, Arnd (Autor)
Rautenberg, Beate (Autor)
Reimer, Toralf (Autor)
Schmidt, Marcus (Autor)
Weide, Rudolf (Autor)
Wimberger, Pauline (Autor)
Nabieva, Naiba (Autor)
Roos, Christian (Autor)
Woeckel, Achim (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
